|Headquarters||Weston, Ontario, Canada|
|Dr. Bernard Sherman, CEO
Jack M. Kay, President 
|Products||Generic Pharmaceutical Drugs|
|Revenue||CAD$2 billion+ (in world wide sales)|
Number of employees
|10,000+ in research, development, manufacturing and distribution facilities world-wide|
Apotex is a Canadian pharmaceutical corporation. Founded in 1974, the company is the largest producer of generic drugs in Canada, with sales exceeding $2 billion (CAD) a year. The company produces more than 300 generic pharmaceuticals in approximately 4000 dosages, and 600 molecules under development. Apotex exports products to over 115 countries around the globe. There are more prescriptions filled with Apotex products in Canada than that of any other pharmaceutical company.
The company has two main divisions: medical research and development; and biotechnology. The biotechnology division is divided into three subsidiaries.
Apotex owns 61% of Cangene Corp., a Winnipeg-based biopharmaceutical company, according to Cangene's 2007 annual report. Cangene's business focuses are hyperimmunes, contract manufacturing, biopharmaceuticals and biodefense against infectious diseases such as smallpox, hepatitis B and anthrax. Its products include WinRho SDF. In February 2014, Emergent BioSolutions, an American company based in Rockville, Maryland, acquired Cangene Corporation.
In 1991, Apotex opened Apotex Fermentation in Winnipeg to develop fermentation-based technologies for the production of Active Pharmaceutical Ingredients (APIs) and to manufacture APIs for eventual sale as final dosage forms in Canada and internationally. The factory employs 150 people.
In January 2004, ApoPharma was founded. It is the subsidiary responsible for research and development of new chemical entities.
Corporate Social Responsibility
International access to medicine
Over the years, Apotex has provided medicines for international humanitarian support efforts. Since 2012, Apotex has worked in conjunction with The Teasdale-Corti Foundation to provide medicine for St. Mary's Hospital Lacor (also known as Lacor Hospital) in Uganda. Apotex continued to provide medicines for Lacor Hospital in 2013, and in total, has donated approximately $1.2 million in medicines to Lacor Hospital.
In September 2014, in response to the spread of the chikungunya virus in Haiti, Apotex worked with the humanitarian organization Direct Relief to donate more than $2.2 million in medical aid to the country.
In 2009, Apotex began providing medicines to the Mully Children’s Family Foundation, an organization located outside of Nairobi, Kenya that is dedicated to rescuing and supporting orphaned and homeless children. Thus far, Apotex has provided three shipments of medications to the Foundation.
Philanthropy in Canada
As of 2008, Apotex had given more than $16 million to pharmacy schools across Canada, and in 2008, Apotex donated $1.5 million to The University of Saskatchewan's College of Pharmacy, which was the largest donation given to the College of Pharmacy.
On August 22, 2013, Apotex announced that it would donate $10 million toward the construction of the new Humber River Hospital (HRH) in Toronto, Canada. Apotex's donation would go towards the building of Humber River Hospital's Emergency Department.
Creation of the Apotex Foundation
Apotex founded the Apotex Foundation, a privately held charitable organization, which has donated over $17 million in medicines over the last 10 years. Critical medicines have been shipped to every disaster zone around the globe to provide assistance to humans in need. Apotex was also the only Canadian company to develop and manufacture a combination drug for AIDS patients in Rwanda.
Problems with regulator
Apotex received a warning letter from the U.S. Food and Drug Administration (FDA) regarding the Etobicoke plant on June 25, 2009 for good manufacturing practice (GMP) violations. It also received a warning letter citing similar GMP violations in the Signet plant on March 29, 2010. FDA issued an import ban on all drugs manufactured at these two plants and prevented the company from seeking new marketing authorizations in the U.S on August 28, 2009. The import ban was subsequently lifted on May 6, 2011. On February 29, 2012, Apotex filed a claim to the International Centre for Settlement of Investment Disputes seeking arbitration with the U.S.A. In the filing, Apotex cited unfair treatment by FDA which constituted a violation of the North American Free Trade Agreement (NAFTA). Apotex further claimed that the action of FDA ‘decimated its business’. On August 26, 2014, NAFTA tribunal rejected Apotex’s claim.
FDA inspected the same plants again in 2013 and issued warning letters for more problems. In April 2014, FDA banned a manufacturing plant owned by Apotex in Bangalore, India. In the warning letter, FDA indicated that the plant routinely deleted failed test results and replaced with retest results that passed. FDA found that the violations are systemic and were dated back for many years, having the same issues noted in past inspections since 2006.
On 17 May 2013, a group of pregnant Canadian women filed a class-action lawsuit against Apotex, after it was discovered that the company's recalled birth control pill packages contained more placebos than usual.
- "SEC Info - Sherman Bernard C, et al. - SC 13D - Counsel Corp - On 12/29/03". Retrieved 2009-02-17.
- "Apotex Corporation Information". Retrieved March 21, 2012.
- Press Release (21 February 2014). "Emergent BioSolutiions Completes Acquisition of Cangene Corporation". Emgergent Biosolutions. Retrieved 17 June 2014.
- "Haiti - Health : 50% of the population could be affected by the chikungunya epidemic". haitilibre.com. December 9, 2014. Retrieved December 9, 2014.
- "Humanity’s capacity for good rises above". insidehalton.com. January 7, 2009. Retrieved December 9, 2014.
- "Apotex Inc. donates $1.5 million to college of pharmacy". canada.com. 24 September 2008. Retrieved December 9, 2014.
- "Under-construction Humber River Hospital receives $10-million boost from Apotex". insidetoronto.com. 22 August 2013. Retrieved December 9, 2014.
- FDA (June 25, 2009). "Warning Letter". Retrieved March 21, 2012.
- FDA (March 29, 2010). "Warning Letter". Retrieved March 21, 2012.
- Silverman, Ed (May 20, 2011). "Apotex creeps out of the FDA dog house". Pharmalot.com. Retrieved March 21, 2012.
- Palmer, Eric (March 19, 2012). "Apotex says FDA import ban, delays ‘decimated’ its business". fiercepharmamanufacturing.com. Retrieved March 21, 2012.
- Palmer, Eric (28 August 2014). "NAFTA says FDA was in its rights to ban Apotex plants". fiercepharmamanufacturing.com. Retrieved 8 September 2014.
- Palmer, Eric (17 June 2014). "FDA says Apotex India plant has faked data for years". fiercepharmamanufacturing.com. Retrieved 17 June 2014.
- Palmer, Eric (20 May 2013). "Women want Apotex to pay for unwanted pregnancies". fiercepharma.com. Retrieved 17 June 2014.